Insider buying last 90 days
No open-market insider purchases were filed for TYRA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TYRA insider filing, plotted on the chart in Gekko.Open TYRA in Gekko
NASDAQ: TYRA
Tyra Biosciences (TYRA) Stock Analysis & Forecast
Oct 12 close
$19.60−0.34 (−1.7%)
Gekko Brief
AI summaryOct 12 closeThis week, Tyra Biosciences draws attention from a securities fraud investigation announced by Pomerantz LLP, tied to a stock price drop following a September 9, 2026 announcement of initial Phase 2 results for its drug dabogratinib. Separately, Raymond James reiterated a Strong Buy rating and a $50.00 price target on Tyra, following a fireside chat with the company's CEO that focused on dabogratinib's potential in treating non-muscle invasive bladder cancer and other conditions.
Shares close at $19.60, down 1.7%, sitting below both the 50-day average of $24.53 and the 200-day average of $30.39, with the 50-day below the 200-day. Three-month and six-month returns stand at -40.4% and -45%, though the one-year return remains positive at 41.8%. The GekkoIndex reads 66.8, placing the stock in the Accumulation zone. Price sits 35.2% below Gekko Fair Value of $30.23.
Tyra's next earnings report is scheduled for 4 November 2026, after close, 23 days away and inside a typical 20-trading-day holding window; the prior report on 4 August 2026 saw a -19.8% reaction, with an average absolute reaction of 5.9% across past quarters. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point in the calendar shows a 20-trading-day average return of 18% over 5 years, with gains in 3 of those years. Analyst coverage from 11 firms shows unanimous buy ratings, with a consensus target of $47.45.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Tyra Biosciences price vs fair value
Close $19.60200-day averageGekko Fair Value $30.23
Tyra Biosciences quick facts
- Market cap
- $1.17B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.39
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.75
- Volume
- 334,395 avg 930,181
- 1-year return
- +41.8%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±12.3%
- 50-day average
- $24.53
- 200-day average
- $30.39
- Next earnings
- Nov 4 after close
- Shares outstanding
- 68.76M
Tyra Biosciences swing-trade checklist
Tyra Biosciences scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $19.60 is below the 50-day ($24.53) and 200-day ($30.39) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
66.8, Accumulation
Reading 66.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
35.2% below
Price is 35.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+18.0% on average
From this point in the calendar, the next 20 trading days averaged +18% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Tyra Biosciences stock chart and price history
Tyra Biosciences closed at $19.60 on Oct 12, 2026, +41.8% over the past year, inside a 52-week range of $13.29 to $40.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.0%
- 3 months
- −40.4%
- 6 months
- −45.0%
- 1 year
- +41.8%
The full TYRA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TYRA in Gekko
Follow Tyra Biosciences through every session
Put TYRA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TYRA in GekkoFree for 7 days. No credit card required.
About Tyra Biosciences
Tyra Biosciences works on early-stage drug candidates aimed at cancers that develop resistance to existing therapies. Its best-known candidate, TYRA-300, is designed to selectively block FGFR3 and is being developed for muscle-invasive bladder cancer. The company has not yet brought a product to market, with its work still in the preclinical stage.
Alongside this lead candidate, Tyra is developing additional programs targeting FGFR2 changes linked to bile duct cancer, FGFR3 mutations tied to achondroplasia, RET kinase abnormalities, and cancers driven by FGFR4. These efforts draw on an in-house approach called the SNAP platform, which uses repeated structural snapshots of molecules to guide and speed up the design of new compounds. The company's activities center on building out this pipeline rather than on existing commercial products.
Tyra Biosciences was established in 2018 and is headquartered in Carlsbad, California. Its shares are listed on the NASDAQ under the ticker TYRA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- tyra.bio
Tyra Biosciences GekkoIndex: the smart money zone
Tyra Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.8, in the Accumulation zone, up 1.3 points over five sessions.
66.8Accumulation
Up 1.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +2.3% | +4.0% | ||
| Accumulation (current zone) | 190 | +0.3% | −1.8% | ||
| Neutral | 406 | +1.2% | +4.5% | ||
| Distribution | 33 | −2.8% | +1.3% | ||
| Selling | 7 | Too few readings yet | |||
Average TYRA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the TYRA price, zone by zone.Track TYRA in Gekko
Is Tyra Biosciences stock overvalued? Gekko Fair Value
Tyra Biosciences trades 35.2% below Gekko Fair Value of $30.23, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Tyra Biosciences shares are worth, recalculated every trading day.
$30.23
Gekko Fair Value, Oct 10, 2026
35.2% Undervalued
At the end of Aug 2026 the price was 42.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TYRA in Gekko
Tyra Biosciences insider and Congress trading
No open-market insider purchases were filed for Tyra Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TYRA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TYRA, plotted on the chart in Gekko.Open TYRA in Gekko
Buybacks
Tyra Biosciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2024
- $251K
- As a share of market cap
- 0.02%
From company filings.
Tyra Biosciences earnings: next date and track record
Tyra Biosciences reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.67
3 of 8reports beat the EPS estimate
±5.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.69 est −$0.65 | — | −19.8% |
| May 13, 2026 | −$0.64 est −$0.58 | — | +4.7% |
| Mar 2, 2026 | −$0.57 est −$0.53 | — | −0.9% |
| Nov 5, 2025 | −$0.50 est −$0.50 | — | −4.8% |
| Aug 14, 2025 | −$0.47 est −$0.53 | — | −0.2% |
| May 8, 2025 | −$0.47 est −$0.49 | — | +10.5% |
| Nov 7, 2024 | −$0.41 est −$0.40 | — | −5.9% |
| Aug 7, 2024 | −$0.32 est −$0.41 | — | +0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Tyra Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Tyra Biosciences is $47.45, +142.1% from the last close, from 11 firms rating the stock in the last 90 days.
$47.45consensus 12-month target, +142.1% from the last close
Now $19.60Avg $47.45
Low $29High $59
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 30 | Barclays | $59 | +201.0% |
| Sep 23 | Raymond James | $50 | +155.1% |
| Sep 22 | Oppenheimer | $40 | +104.1% |
| Sep 22 | Canaccord Genuity | $50 | +155.1% |
| Sep 22 | H.C. Wainwright | $29 | +48.0% |
−1.8%average 20-day move after past Accumulation readings
+18.0%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Tyra Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Tyra Biosciences averaged +18.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +12.2% | 4 of 5 |
| Next 10 trading days | +15.2% | 4 of 5 |
| Next 15 trading days | +8.4% | 3 of 5 |
| Next 20 trading days | +18.0% | 3 of 5 |
| Next 30 trading days | +15.3% | 3 of 5 |
For scale, TYRA’s typical 20-trading-day move in either direction is about 12.3%.
Tyra Biosciences market cap and key statistics
Tyra Biosciences’s market cap is $1.17B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.17B
- EPS, TTM
- −$2.39
- Gekko Fair Value
- $30.23
Trading
- Volume
- 334,395
- Avg volume, 20 days
- 930,181
- 52-week high
- $40.65
- 52-week low
- $13.29
- Shares outstanding
- 68.76M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -45.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.75
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±12.3%
Tyra Biosciences stock news this week
Coverage of Tyra Biosciences this week reads positive: 2 positive, 0 neutral and 1 negative headlines.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR Newswire, Oct 9
- Raymond James reiterates Strong Buy on Tyra Biosciences stockInvesting.com, Oct 7
- Raymond James reiterates Strong Buy on Tyra Biosciences stock By Investing.comInvesting.com Canada, Oct 6
Tyra Biosciences peers
Tyra Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Tyra Biosciences stock FAQ
What is Tyra Biosciences’s market cap?
Tyra Biosciences’s market cap is $1.17B at the Oct 12, 2026 close of $19.60, with 68.76M shares outstanding.
What is the Tyra Biosciences stock forecast?
The consensus analyst 12-month price target for Tyra Biosciences is $47.45, +142.1% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Tyra Biosciences stock overvalued or undervalued?
On Gekko’s estimate Tyra Biosciences is undervalued: the Oct 12, 2026 close of $19.60 is 35.2% below Gekko Fair Value of $30.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Tyra Biosciences report earnings next?
Tyra Biosciences is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.67 per share. Tyra Biosciences beat the earnings estimate in 3 of its last 8 reports, moving 5.9% on average across the report.
What is Tyra Biosciences’s 52-week high and low?
Tyra Biosciences’s 52-week high is $40.65 and its 52-week low is $13.29; it closed at $19.60 on Oct 12, 2026, +41.8% over the past year.
Is Tyra Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Tyra Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.